CA2806399A1 - Polypeptides d'insuline exprimes de facon recombinante et utilisations de ceux-ci - Google Patents

Polypeptides d'insuline exprimes de facon recombinante et utilisations de ceux-ci Download PDF

Info

Publication number
CA2806399A1
CA2806399A1 CA2806399A CA2806399A CA2806399A1 CA 2806399 A1 CA2806399 A1 CA 2806399A1 CA 2806399 A CA2806399 A CA 2806399A CA 2806399 A CA2806399 A CA 2806399A CA 2806399 A1 CA2806399 A1 CA 2806399A1
Authority
CA
Canada
Prior art keywords
polypeptide
xaa
insulin
thr
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2806399A
Other languages
English (en)
Inventor
Thomas M. Lancaster
Sylaja Murikipudi
Rassol Laleau
Todd C. Zion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmartCells Inc
Original Assignee
SmartCells Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmartCells Inc filed Critical SmartCells Inc
Publication of CA2806399A1 publication Critical patent/CA2806399A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA2806399A 2010-07-28 2011-07-22 Polypeptides d'insuline exprimes de facon recombinante et utilisations de ceux-ci Abandoned CA2806399A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36860710P 2010-07-28 2010-07-28
US61/368,607 2010-07-28
PCT/US2011/045008 WO2012015692A2 (fr) 2010-07-28 2011-07-22 Polypeptides d'insuline exprimés de façon recombinante et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
CA2806399A1 true CA2806399A1 (fr) 2012-02-02

Family

ID=45530663

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2806399A Abandoned CA2806399A1 (fr) 2010-07-28 2011-07-22 Polypeptides d'insuline exprimes de facon recombinante et utilisations de ceux-ci

Country Status (6)

Country Link
US (1) US9074015B2 (fr)
EP (1) EP2598527A4 (fr)
JP (1) JP2013535467A (fr)
AU (1) AU2011282988A1 (fr)
CA (1) CA2806399A1 (fr)
WO (1) WO2012015692A2 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG173112A1 (en) * 2009-01-28 2011-08-29 Smartcells Inc Conjugate based systems for controlled drug delivery
US9475709B2 (en) 2010-08-25 2016-10-25 Lockheed Martin Corporation Perforated graphene deionization or desalination
US9028663B2 (en) * 2012-03-21 2015-05-12 Lockheed Martin Corporation Molecular separation device
US9834809B2 (en) 2014-02-28 2017-12-05 Lockheed Martin Corporation Syringe for obtaining nano-sized materials for selective assays and related methods of use
US10980919B2 (en) 2016-04-14 2021-04-20 Lockheed Martin Corporation Methods for in vivo and in vitro use of graphene and other two-dimensional materials
US10376845B2 (en) 2016-04-14 2019-08-13 Lockheed Martin Corporation Membranes with tunable selectivity
US10653824B2 (en) 2012-05-25 2020-05-19 Lockheed Martin Corporation Two-dimensional materials and uses thereof
US10118130B2 (en) 2016-04-14 2018-11-06 Lockheed Martin Corporation Two-dimensional membrane structures having flow passages
US9744617B2 (en) 2014-01-31 2017-08-29 Lockheed Martin Corporation Methods for perforating multi-layer graphene through ion bombardment
PT2963056T (pt) * 2013-02-26 2020-02-19 Hanmi Pharm Ind Co Ltd Análogo de insulina e utilização do mesmo
TW201504140A (zh) 2013-03-12 2015-02-01 Lockheed Corp 形成具有均勻孔尺寸之多孔石墨烯之方法
US9572918B2 (en) 2013-06-21 2017-02-21 Lockheed Martin Corporation Graphene-based filter for isolating a substance from blood
KR101625746B1 (ko) 2013-09-23 2016-05-31 순천대학교 산학협력단 프로미니인슐린 재조합 단백질이 발현된 형질전환 식물 및 이의 제조방법
MA46146A1 (fr) 2014-01-20 2020-12-31 Hanmi Pharm Ind Co Ltd Insuline a action prolongée et utilisation associée
WO2015116946A1 (fr) 2014-01-31 2015-08-06 Lockheed Martin Corporation Perforation de matériaux bidimensionnels à l'aide d'un large champ ionique
KR20160142282A (ko) 2014-01-31 2016-12-12 록히드 마틴 코포레이션 다공성 비-희생 지지층을 사용하여 2차원 물질로 복합 구조를 형성하기 위한 프로세스
CA2942496A1 (fr) 2014-03-12 2015-09-17 Lockheed Martin Corporation Membranes de separation formees a partir de graphene perfore
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
JP2017534311A (ja) 2014-09-02 2017-11-24 ロッキード・マーチン・コーポレーション 二次元膜材料をベースとする血液透析膜および血液濾過膜、ならびにそれを用いた方法
AU2016303048A1 (en) 2015-08-05 2018-03-01 Lockheed Martin Corporation Perforatable sheets of graphene-based material
MX2018001559A (es) 2015-08-06 2018-09-27 Lockheed Corp Modificacion de nanoparticula y perforacion de grafeno.
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
CN105061566A (zh) * 2015-09-05 2015-11-18 苏州普罗达生物科技有限公司 拟胰岛素多肽及其应用
WO2017180133A1 (fr) 2016-04-14 2017-10-19 Lockheed Martin Corporation Procédés permettant la surveillance et la commande in situ d'une formation ou cicatrisation de défaut
KR20190018411A (ko) 2016-04-14 2019-02-22 록히드 마틴 코포레이션 그래핀 결함의 선택적 계면 완화
CA3020686A1 (fr) 2016-04-14 2017-10-19 Lockheed Martin Corporation Procede de traitement de feuilles de graphene pour un transfert a grande echelle a l'aide d'un procede a flottaison libre
WO2017207754A1 (fr) 2016-06-02 2017-12-07 Sanofi Conjugués constitués d'un agent pharmaceutique et d'une fraction apte se lier à une protéine de détection du glucose
JP7158378B2 (ja) 2016-09-23 2022-10-21 ハンミ ファーマシューティカル カンパニー リミテッド インスリン受容体との結合力が減少された、インスリンアナログ及びその用途
JP7170332B2 (ja) * 2016-12-09 2022-11-14 アクストン バイオサイエンシズ コーポレーション インスリンとｆｃの融合物および使用方法
US11752216B2 (en) 2017-03-23 2023-09-12 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof
EP3668892A1 (fr) 2017-08-17 2020-06-24 Novo Nordisk A/S Nouveaux analogues d'insuline acylés et leurs utilisations
WO2019106122A1 (fr) 2017-12-01 2019-06-06 Sanofi Nouveaux conjugués constitués d'un agent pharmaceutique et d'une fraction pouvant se lier à une protéine de détection du glucose
EP3727424A4 (fr) * 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. Systèmes à base de conjugués pour l'administration contrôlée d'insuline
AU2019291945A1 (en) 2018-06-29 2021-01-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
CN114846025A (zh) 2019-12-19 2022-08-02 阿卡斯通生物科学公司 超长效胰岛素-Fc融合蛋白及其使用方法
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
DK3972987T3 (da) 2020-04-10 2023-07-31 Akston Biosciences Corp Antigenspecifik immunterapi til COVID-19-fusionsproteiner og fremgangsmåder til anvendelse deraf
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
WO2023004406A2 (fr) 2021-07-23 2023-01-26 Akston Biosciences Corporation Protéines de fusion insuline-fc et méthodes d'utilisation pour traiter le cancer

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591574A (en) 1968-05-29 1971-07-06 American Home Prod Tri-n-phenylglycyl derivatives of insulin
DE1793517C3 (de) 1968-09-28 1974-12-05 Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt N(Al),N(B29>Bis-(tert.-butyloxycarbonyl)-insulin und Verfahren zu seiner Herstellung
US3847890A (en) 1971-11-01 1974-11-12 A Green Acidic monosaccharide-substituted proteins
US4377567A (en) 1978-10-02 1983-03-22 The Procter & Gamble Company Lipid membrane drug delivery
DE2964024D1 (en) 1978-10-02 1982-12-16 Procter & Gamble Liposomes for drug delivery and composition containing a liposome drug system
US4348387A (en) 1979-07-31 1982-09-07 The Rockefeller University Method and system for the controlled release of biologically active substances to a body fluid
JPS608000B2 (ja) 1980-04-11 1985-02-28 呉羽化学工業株式会社 アミノフエニル誘導体及び該誘導体を含有する生理活性剤
US4444683A (en) 1982-11-17 1984-04-24 University Of Utah Glycosylated insulin derivatives
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
EP0119650A3 (fr) 1983-03-21 1987-09-30 THE PROCTER & GAMBLE COMPANY Conjugués de galactosyl-insuline utilisés dans le traitement des diabétiques
US4863896A (en) 1984-05-03 1989-09-05 Technology Unlimited, Inc. Diabetic control by combined insulin forms
US5239062A (en) 1986-03-20 1993-08-24 Dana-Farber Cancer Institute, Inc. Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity
US5395924A (en) 1986-03-20 1995-03-07 Dana-Farber Cancer Institute, Inc. Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity
US5527524A (en) 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
DK111489D0 (da) 1989-03-08 1989-03-08 Novo Nordisk As Peptider
AU628674B2 (en) 1989-10-19 1992-09-17 Nippon Oil And Fats Company, Limited Polymer complexes of a sugar response type
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
DK300090D0 (da) * 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
GB9200638D0 (en) 1992-01-10 1992-03-11 Leicester Polytechnic Drug system
CA2107683C (fr) 1992-02-13 2004-07-20 Dale G. Swan Immobilisation d'especes chimiques dans des matrices reticulees
GB9316895D0 (en) 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
GB9313484D0 (en) 1993-06-30 1993-08-11 Univ Montfort Drug system ii
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
HRP940432B1 (en) * 1994-08-05 2003-10-31 Pliva Pharm & Chem Works Dna sequences encoding biosynthetic insulin precursors and process for preparation of insulin
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
DK0871474T4 (da) * 1994-12-29 2012-01-09 Ferring Int Ct Sa Fremstilling af human insulin
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
CN1120707C (zh) 1995-11-22 2003-09-10 约翰斯·霍普金斯大学 增强生物分子的细胞摄取的配体
US5723589A (en) 1995-12-21 1998-03-03 Icn Pharmaceuticals Carbohydrate conjugated bio-active compounds
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
AU5549998A (en) 1997-01-24 1998-08-18 Novo Nordisk A/S Synthetic leader peptide sequences
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
EP1071703B1 (fr) 1998-04-15 2005-07-20 Novo Nordisk A/S NOUVEAU PROCEDE DE SEPARATION DE PROTEINES AU MOYEN D'UN ELUANT RENFERMANT DES IONS Ca++
DE69933216T2 (de) 1998-06-15 2007-09-20 GTC Biotherapeutics, Inc., Framingham Erythropoietin-analog-menschliches serum-albumin fusionsprotein
US6844166B1 (en) 1998-09-11 2005-01-18 Sensor Technologies Inc. Recombinant reduced valency carbohydrate binding ligands
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
US6521738B2 (en) 1999-12-29 2003-02-18 Novo Nordisk A/S Method for making insulin precursors and insulin precursor analogs
US6777207B2 (en) 1999-12-29 2004-08-17 Novo Nordisk A/S Method for making insulin precursors and insulin precursor analogues having improved fermentation yield in yeast
WO2001072323A2 (fr) 2000-03-24 2001-10-04 Genentech, Inc. Utilisation de l'insuline pour traiter des affections des cartilages
WO2001092334A1 (fr) 2000-06-02 2001-12-06 Novo Nordisk A/S Liberation glucose-dependante d'insuline par des derives d'insuline detectant le glucose
US7316999B2 (en) 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
AU2002258490A1 (en) 2001-03-12 2003-06-17 Clemson University Polysaccharide-based polmerizable hydrogels
US7105314B2 (en) 2001-04-02 2006-09-12 Novo Nordisk A/S Method for making human insulin precursors
US7049286B2 (en) * 2001-08-30 2006-05-23 Diatos, S.A. Insulin conjugates and methods of use thereof
EP2292271A3 (fr) 2001-10-10 2011-09-14 BioGeneriX AG Remodelage et glycoconjugation des anticorps
WO2003035011A2 (fr) 2001-10-26 2003-05-01 The Uab Research Foundation Conjugues multimedicaments multiligands permettant une administration ciblee de medicaments
US7317000B2 (en) 2001-12-02 2008-01-08 Novo Nordisk A/S Glucose-dependent insulins
US7349688B2 (en) 2001-12-07 2008-03-25 Ntt Docomo, Inc. Mobile communications terminal, application program execution state control method, and execution state control computer program product
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
CA2493674A1 (fr) 2002-07-19 2004-01-29 The Regents Of The University Of California Dendrimeres servant de translocateurs moleculaires
WO2004056311A2 (fr) 2002-12-17 2004-07-08 Massachusetts Institute Of Technology Systemes reagissant a des stimulis pour l'administration regulee de medicaments
AU2003294912B2 (en) 2002-12-20 2009-06-04 Greenovation Biotech Gmbh Production of heterologous glycosylated proteins in bryophyte cells
WO2006088473A2 (fr) 2004-04-23 2006-08-24 Panduranga Rao Koritala Microparticules et nanoparticules pour l'administration transmuqueuse d'agents therapeutiques et diagnostiques
WO2006008238A1 (fr) 2004-07-16 2006-01-26 Novo Nordisk A/S Procede d'acylation selective
CA2580313C (fr) 2004-07-19 2016-03-15 Biocon Limited Conjugues insuline-oligomere, preparations et utilisations de ceux-ci
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
US20070207498A1 (en) 2005-02-24 2007-09-06 Lifescan, Inc. Design and construction of dimeric concanavalin a mutants
US20060247154A1 (en) 2005-02-24 2006-11-02 Lifescan, Inc. Concanavalin a, methods of expressing, purifying and characterizing concanavalina, and sensors including the same
WO2006102762A1 (fr) 2005-04-01 2006-10-05 Mcmaster University Microgels reagissant au glucose
CA2624867A1 (fr) 2005-10-10 2007-04-19 N.V. Organon Compose antithrombotique
US7517856B2 (en) 2005-10-11 2009-04-14 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
US20070099820A1 (en) 2005-10-19 2007-05-03 Smartcells, Inc. Polymer-drug conjugates
JP2009527526A (ja) * 2006-02-21 2009-07-30 ノボ・ノルデイスク・エー／エス 単鎖インスリンのアナログとその製薬的製剤
ATE482977T1 (de) 2006-02-27 2010-10-15 Novo Nordisk As Insulinderivate
DE102006031955A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
WO2008036147A2 (fr) 2006-07-24 2008-03-27 Duke University Administration de médicament avec biopolymères sensibles aux stimuli
KR101400105B1 (ko) 2006-07-25 2014-06-19 리폭센 테크놀로지즈 리미티드 Ｎ-말단 폴리시알화
FR2904315B1 (fr) 2006-07-26 2012-12-14 Centre Nat Rech Scient Composes pyridaziniques et pyrroliques, procedes d'obtention et applications
WO2008065372A2 (fr) 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Polypeptides d'érythropoïétine modifiés et utilisation de ceux-ci dans des traitements
CN101273961A (zh) 2007-03-30 2008-10-01 中国人民解放军总医院 葡萄糖敏感水凝胶
EP2134853B1 (fr) * 2007-04-03 2018-07-18 Oxyrane UK Limited Glycosylation de molécules
US20090053167A1 (en) 2007-05-14 2009-02-26 Neose Technologies, Inc. C-, S- and N-glycosylation of peptides
WO2009033588A2 (fr) 2007-09-11 2009-03-19 F. Hoffmann-La-Roche Ag Système d'administration auto-contrôlée d'insuline
WO2009059450A1 (fr) 2007-11-05 2009-05-14 Shanghai Jiaotong University Administration de médicament dirigée par un ligand peptidique
NZ584825A (en) 2007-11-20 2013-03-28 Ambrx Inc Modified insulin polypeptides and their uses
US20100286067A1 (en) 2008-01-08 2010-11-11 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
RU2381238C2 (ru) 2008-01-31 2010-02-10 Ордена Трудового Красного Знамени Институт нефтехимического синтеза им. А.В. Топчиева Российской академии наук (статус государственного учреждения) Способ получения глюкозочувствительных полимерных гидрогелей
MX2010009033A (es) 2008-02-19 2010-12-21 Biocon Ltd Un metodo para obtener insulinas heterologas purificadas expresadas en levadura.
GB0812019D0 (en) * 2008-07-02 2008-08-06 Asterion Ltd Insulin
CA2750252A1 (fr) 2009-01-28 2010-08-05 Smartcells, Inc. Conjugues synthetiques et leurs utilisations
SG173112A1 (en) 2009-01-28 2011-08-29 Smartcells Inc Conjugate based systems for controlled drug delivery
CA2750245A1 (fr) 2009-01-28 2010-08-05 Smartcells, Inc. Matieres reticulees a base d'aptameres polynucleotidiques et leurs utilisations
PE20120582A1 (es) 2009-01-28 2012-05-26 Smartcells Inc Conjugados de insulina cristalina
WO2010088261A1 (fr) 2009-01-28 2010-08-05 Smartcells, Inc. Lectines de site de liaison modifiées et usage correspondant
AU2010208381A1 (en) 2009-01-28 2011-08-04 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
EP2448962B1 (fr) 2009-06-30 2016-10-19 Novo Nordisk A/S Dérivés d'insuline

Also Published As

Publication number Publication date
AU2011282988A1 (en) 2013-01-31
US20130190476A1 (en) 2013-07-25
WO2012015692A3 (fr) 2012-04-19
WO2012015692A2 (fr) 2012-02-02
EP2598527A2 (fr) 2013-06-05
JP2013535467A (ja) 2013-09-12
EP2598527A4 (fr) 2014-01-08
US9074015B2 (en) 2015-07-07

Similar Documents

Publication Publication Date Title
US9074015B2 (en) Recombinantly expressed insulin polypeptides and uses thereof
US11167035B2 (en) Insulin compositions and method of making a composition
US20160289290A1 (en) N-glycosylated insulin analogues
US8722620B2 (en) Insulin derivatives
KR20170125853A (ko) 글루코스 조절된 구조 전환을 포함하는 인슐린 유사체
US20240025957A1 (en) Insulin Derivative
KR20210013300A (ko) 장기 작용성 성장 호르몬 및 이의 제조 방법
JP2009522231A5 (fr)
EP4282473A2 (fr) Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation
EP2925345B1 (fr) Méthode de préparation d'insuline et d'analogues d'insuline à base du peptide de la partie terminale carboxy (ctp) o-glycosylé
WO2021136303A1 (fr) Composé glp-1 à action prolongée
US9585942B2 (en) Insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, use of the insulin analogue, dosage method and method of treatment of diabetes
CA3235948A1 (fr) Compositions et procedes d'administration orale

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130123

FZDE Dead

Effective date: 20160914